icon bookmark-bicon bookmarkicon cameraicon checkicon chevron downicon chevron lefticon chevron righticon chevron upicon closeicon v-compressicon downloadicon editicon v-expandicon fbicon fileicon filtericon flag ruicon full chevron downicon full chevron lefticon full chevron righticon full chevron upicon gpicon insicon mailicon moveicon-musicicon mutedicon nomutedicon okicon v-pauseicon v-playicon searchicon shareicon sign inicon sign upicon stepbackicon stepforicon swipe downicon tagicon tagsicon tgicon trashicon twicon vkicon yticon wticon fm

London asks regulator to assess Oxford/AstraZeneca Covid-19 vaccine amid concerns over trial’s robustness

London asks regulator to assess Oxford/AstraZeneca Covid-19 vaccine amid concerns over trial’s robustness
UK regulators are being asked to access AstraZeneca’s vaccine with the view that four million jabs could be ready for rollout in December despite fears over insufficient trial data.

UK Health Secretary, Matt Hancock, said in a statement released on Friday that the government was working “tirelessly” to ensure a vaccine could be delivered to the British people and had formally asked the Medicines and Healthcare products Regulatory Agency (MHRA) to evaluate. 

“We have formally asked the regulator to assess the Oxford/AstraZeneca vaccine, to understand the data and determine whether it meets rigorous safety standards. This letter is an important step towards deploying a vaccine as quickly as safely possible,” Hancock said.

The government has already formally requested that the MHRA evaluate the Pfizer/BioNTech vaccine after it was shown to be 95% effective.

There was much cheer on Monday as data released by the UK pharmaceutical giant showed the vaccine to be up to 90 percent effective when given as a half dose followed by a full dose.  

However, the vaccine showed only 62 percent efficacy when the full two doses were administered to trial participants.

Also on rt.com I’m an epidemiology professor and I have some genuine concerns about the AstraZeneca Covid vaccine. Here’s why…

AstraZeneca CEO Pascal Soriot said on Thursday that the jab would be tested again – something that would probably not delay the vaccine’s authorization, he said.

The mixed data raised experts’ concerns, fueled by allegations that the 90-percent effective result was achieved because of the young age of those tested.

Other vaccines, including the Pfizer and Moderna ones, have been shown to be more effective against Covid-19 during stage three trials, while Russian-developed Sputnik V has demonstrated 95 percent efficacy in early trial data.


Also on rt.com Efficacy vs safety? AstraZeneca vaccine is ‘busted flush’ IF it cannot help elderly – but US jabs may be worse, UK doctor tells RT

Like this story? Share it with a friend!

Dear readers and commenters,

We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system.

Sorry for the inconvenience, and looking forward to your future comments,

RT Team.